Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

VAL cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (14) Akt (2) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (5) Apoptosis (3) Aurora Kinase (1) Biochemical Assay Reagents (1) c-Kit (1) c-Met/HGFR (2) Caspase (4) Cathepsin (2) CDK (1) Dipeptidyl Peptidase (2) Drug Derivative (1) Drug-Linker Conjugates for ADC (2) ERK (2) Glycosidase (1) HSV (1) Integrin (1) MALT1 (1) Microtubule/Tubulin (2) PROTAC-Linker Conjugates for PAC (1) SARS-CoV (1) TGF-β Receptor (1) Topoisomerase (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (28) Infection (2) Inflammation/Immunology (4) Neurological Disease (2)
Click Chemistry:	DBCO (1) Azide (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Click Chemistry

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor Programmed Cell Death 4 (PDCD4)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125956

Aurkin A	Aurora Kinase Apoptosis	Cancer
Aurkin A is an allosteric inhibitor for the interaction between Aurora A Kinase (also known also Aurka) and TPX2, through targeting the TPX2 binding sites with K_d of 3.77 μM. Aurkin A can disrupt polyploidy induced by Alisertib (HY-10971) and increase apoptosis of tumor cells. Aurkin A can be used in research on mitosis and cancer .

HY-P4322

H-Ile-Lys-Val-Ala-Val-OH 1 Publications Verification	ERK Akt	Neurological Disease Cancer
H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating MAPK/ERK1/2 and PI3K/Akt signalling pathways .

HY-P3726

Lys-Gln-Ala-Gly-Asp-Val	Integrin	Inflammation/Immunology Cancer
Lys-Gln-Ala-Gly-Asp-Val (KQAGDV) is the six most carboxyl-terminal amino acids in the fibrinogen γ-chain sequence. Lys-Gln-Ala-Gly-Asp-Val is a cell adhesion peptide which is mediated through the α_2bβ₃ integrin. Lys-Gln-Ala-Gly-Asp-Val is a potent adhesion ligand for smooth muscle cells (SMCs) .

HY-172287

DBCO-PEG2-Val-Cit-PAB-MMAE	ADC Linker	Cancer
DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.

HY-P3972

H-ILE-ARG-VAL-VAL-MET-OH	TGF-β Receptor	Cancer
H-ILE-ARG-VAL-VAL-MET-OH is a pentapeptide from C7 with a domain that supports cell attachment. H-ILE-ARG-VAL-VAL-MET-OH is also the sequence fragment that binds to the thrombospondin-1 (TS1) receptor .

HY-161780

Maleimide-PEG8-Val-Ala-PAB-SNS032	Drug-Linker Conjugates for ADC CDK	Cancer
Maleimide-Val-Ala-PAB-SNS032 is a conjugate of ADC toxin and linker. SNS032 is an inhibitor for CDK, inhibiting the cell cycle at G1/S phase and cell viability of cancer cells. Maleimide-Val-Ala-PAB is a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 can be utilized for the synthesis of ADC molecules .

HY-P4544

Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone	MALT1	Cancer
Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone is a potent MALT1 inhibitor. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone inhibits cell proliferation and migration. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone shows anticancer activity .

HY-152919

Mal-amide-PEG8-Val-Cit-PAB-OH	ADC Linker	Cancer
Mal-amide-PEG8-Val-Cit-PAB-OH is a cleavable ADC linker featuring a maleimide, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB functional group. Maleimide is used to covalently bind free thiols on the cysteine residues of proteins. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery with the help of the PAB structure.

HY-P4532

Ac-Leu-Val-Lys-Aldehyde	Cathepsin	Neurological Disease
Ac-Leu-Val-Lys-Aldehyde is a potent cathepsin B inhibitor with IC₅₀s of 4 nM. Ac-Leu-Val-Lys-Aldehyde significantly reduces quinolinic acid (HY-100807)-induced striatal cell death and causes accumulation of LC3-II .

HY-W800837

t-Boc-N-amido-PEG4-Val-Cit	ADC Linker	Cancer
t-Boc-N-amido-PEG4-Val-Cit is a protease-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit dipeptide. The Val-Cit dipeptide is cleavable by cell proteases and features a carboxylic acid which is free for coupling reactions with amines to form amides. The Boc can be removed under acidic conditions to reveal a free primary amine, which may be used in a variety of reactions such as coupling or reductive amination.

HY-P5989

Calpain inhibitor V Mu-VAL-HPh-FMK	Antibiotic	Infection
Calpain inhibitor V (Mu-Val-HPh-FMK) is a cell-permeable and irreversible inhibitor of calpain that has anti-chlamydial activity .

HY-W800622

Fmoc-PEG4-Val-Cit-PAB-OH	ADC Linker	Cancer
Fmoc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800625

Boc-PEG4-Val-Cit-PAB-OH	ADC Linker	Cancer
Boc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800621

Fmoc-PEG2-Val-Cit-PAB-OH	ADC Linker	Cancer
Fmoc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine for use in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800623

Fmoc-PEG6-Val-Cit-PAB-OH	ADC Linker	Cancer
Fmoc-PEG6-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800624

Boc-PEG2-Val-Cit-PAB-OH	ADC Linker	Cancer
Boc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.

HY-W800814

Azido-PEG8-Amido-Val-Cit-PAB	ADC Linker	Cancer
Azido-PEG8-Amido-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome, the ADC payload will be released only in the cell. Azido will react with DBCO, BCN or other alkyne groups through click chemistry. PEG spacer increases aqueous solubility. Reagent grade, for research purpose.

HY-112099

Mc-Val-Cit-PAB-Cl	ADC Linker	Cancer
Mc-Val-Cit-PAB-Cl is a cleavable ADC linker. Mc-Val-Cit-PAB-Cl can be used to conjugate MMAE and antibody to form antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE with IC₅₀s of 3.3 and 0.95 nM for BJAB and WSU cell lines in cytotoxicity assay).

HY-W011254

Ac-VAD-CHO Ac-VAL-Ala-Asp-CHO	Caspase	Cancer
Ac-VAD-CHO (Ac-Val-Ala-Asp-CHO) is a pan-caspase inhibitor. Ac-VAD-CHO inhibits dissipation of MMP and cytochrome c release in hypoxia-exposed cells .

HY-W800618

NH2-PEG3-Val-Cit-PAB-OH	ADC Linker	Others
NH2-PEG3-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.

HY-W800617

NH2-PEG1-Val-Cit-PAB-OH	ADC Linker	Cancer
NH2-PEG1-Val-Cit-PAB-OH is a cleavable ADC linker intermediate featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.

HY-W800619

NH2-PEG4-Val-Cit-PAB-OH	ADC Linker	Others
NH2-PEG4-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.

HY-W800620

NH2-PEG6-Val-Cit-PAB-OH	ADC Linker	Others
NH2-PEG6-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.

HY-P99803

Clervonafusp alfa VAL-1221	Glycosidase	Others
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .

HY-P4900

Fluorescein-6-carbonyl-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone	Caspase	Others
Fluorescein-6-carbonyl-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone is a cell-permeable, non-toxic inhibitor that binds irreversibly to activated caspase-3 in apoptotic cells. The fluorescence intensity can be measured by flow cytometry, microwell plate reader, or fluorescence microscopy .

HY-157763

Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1	PROTAC-Linker Conjugates for PAC Transmembrane Glycoprotein	Cancer
Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 (Compound 3) is a "linker-payload" component of an antibody-drug conjugate (ADC). Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 selectively delivers the dual-function BTK degrader to B-cell malignancies by targeting the monoclonal antibody of CD79b. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be coupled to the engineered CD79b antibody with cysteine, forming CD79b-3 ADC (ADC linker: (HY-130944); Protac: (HY-163295)).

HY-164729

FZ-AD005	Antibody-Drug Conjugates (ADCs)	Cancer
FZ-AD005 is a DLL3 target ADC compound containing a novel anti-DLL3 antibody, FZ-A038, and a valine–alanine (Val–Ala) dipeptide linker. FZ-AD005 can used in the research of small cell lung cancer .

HY-178219

4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin Apoptosis	Cancer
4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE is a drug-linker conjugate for ADC. 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE contains a linker and bioactive small molecule toxins MMAE (HY-15162). 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE can conjugate with NN2101 (HY-P991293) (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) .

HY-171982

ATII	Biochemical Assay Reagents	Others
ATII (Traseolide), a Polycyclic musk fragrance, is a hydrophobic hapten. ATII has no genotoxicity in the human lymphocytes and the human hepatoma cell line Hep G2. ATII can be bound by antibody M02/05/01 (H93 Val) with superior binding capacity. ATII can be conjugated to carrier proteins for antigen design .

HY-16658

Z-VAD(OMe)-FMK Maximum Cited Publications 193 Publications Verification Z-VAL-Ala-Asp(OMe)-FMK	Caspase	Cancer
Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a cell-permeable and irreversible pan-caspase inhibitor . Z-VAD(OMe)-FMK is an ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitor. Z-VAD(OMe)-FMK irreversibly modifies UCHL1 by targeting the active site of UCHL1 .

HY-141601

Telisotuzumab vedotin 1 Publications Verification ABBV-399	Antibody-Drug Conjugates (ADCs) c-Met/HGFR	Cancer
Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used to study non-small cell lung cancer expressing c-Met protein .

HY-131296

5-A-RU-PABC-Val-Cit-Fmoc 5+ Cited Publications	Drug Derivative	Inflammation/Immunology
5-A-RU-PABC-Val-Cit-Fmoc is the proagent of 5-A-RU . 5-A-RU, a precursor of bacterial Riboflavin, is a mucosal-associated invariant T (MAIT) cells activator. 5-A-RU forms potent MAIT-activating antigens via non-enzymatic reactions with small molecules, such as glyoxal and methylglyoxal, which are derived from other metabolic pathways .

HY-171945

Telisotuzumab Adizutecan ABBV-400; Temab-A	Antibody-Drug Conjugates (ADCs) Topoisomerase c-Met/HGFR	Cancer
Telisotuzumab Adizutecan (ABBV-400) is an anti- c-Met antibody-drug conjugate (ADC). Telisotuzumab Adizutecan consists of a humanized anti-c-Met antibody Telisotuzumab (HY-P99391), a stable and cleavable linker (TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane), a topoisomerase 1 inhibitor (7-MAD-MDCPT) (HY-132162), and the drug-linker conjugate for ADC is TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (HY-171946). Telisotuzumab Adizutecan has a significant anti-tumor activity in advanced solid tumors, such as colorectal, gastric and non-small cell lung cancer .

HY-13233A

Talabostat mesylate 40+ Cited Publications VAL-boroPro mesylate; PT100 mesylate	Dipeptidyl Peptidase	Inflammation/Immunology Cancer
Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC₅₀ < 4 nM; K_i = 0.18 nM) and the inhibitor of fibroblast activation protein (FAP) (IC₅₀ = 560 nM), inhibits DPP8/9 (IC₅₀ = 4/11 nM; K_i = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC₅₀ = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities .

HY-P99612

Farletuzumab ecteribulin MORAb-202	Antibody-Drug Conjugates (ADCs)	Cancer
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

HY-13233

Talabostat VAL-boroPro; PT100	Dipeptidyl Peptidase	Inflammation/Immunology Cancer
Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC₅₀ < 4 nM; K_i = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC₅₀ = 560 nM), inhibits DPP8/9 (IC₅₀ = 4/11 nM; K_i = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC₅₀ = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities .

HY-177578

NN3201	Antibody-Drug Conjugates (ADCs) c-Kit Apoptosis Microtubule/Tubulin ERK Akt Caspase	Cancer
NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (K_D = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research ^[1][2].

HY-108137A

Z-L(D-Val)G-CHN2	Cathepsin HSV SARS-CoV	Infection
Z-L(D-Val)G-CHN2 is the isoform of Z-LVG-CHN2 (HY-108137). Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC₅₀=190 nM) via inhibition of SARS-COV-2 3CL pro protease .

Cat. No.	Product Name	Target	Research Area

HY-P4322

H-Ile-Lys-Val-Ala-Val-OH 1 Publications Verification	ERK Akt	Neurological Disease Cancer
H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating MAPK/ERK1/2 and PI3K/Akt signalling pathways .

HY-P3726

Lys-Gln-Ala-Gly-Asp-Val	Integrin	Inflammation/Immunology Cancer
Lys-Gln-Ala-Gly-Asp-Val (KQAGDV) is the six most carboxyl-terminal amino acids in the fibrinogen γ-chain sequence. Lys-Gln-Ala-Gly-Asp-Val is a cell adhesion peptide which is mediated through the α_2bβ₃ integrin. Lys-Gln-Ala-Gly-Asp-Val is a potent adhesion ligand for smooth muscle cells (SMCs) .

HY-P3703

H-Val-Thr-Cys-Gly-OH	Peptides	Others
H-Val-Thr-Cys-Gly-OH is a cell attachment peptide. H-Val-Thr-Cys-Gly-OH is a bioactive molecule used for cell adhesion or other cell interactions .

HY-P3972

H-ILE-ARG-VAL-VAL-MET-OH	TGF-β Receptor	Cancer
H-ILE-ARG-VAL-VAL-MET-OH is a pentapeptide from C7 with a domain that supports cell attachment. H-ILE-ARG-VAL-VAL-MET-OH is also the sequence fragment that binds to the thrombospondin-1 (TS1) receptor .

HY-P4544

Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone	MALT1	Cancer
Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone is a potent MALT1 inhibitor. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone inhibits cell proliferation and migration. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone shows anticancer activity .

HY-P4532

Ac-Leu-Val-Lys-Aldehyde	Cathepsin	Neurological Disease
Ac-Leu-Val-Lys-Aldehyde is a potent cathepsin B inhibitor with IC₅₀s of 4 nM. Ac-Leu-Val-Lys-Aldehyde significantly reduces quinolinic acid (HY-100807)-induced striatal cell death and causes accumulation of LC3-II .

HY-P5989

Calpain inhibitor V Mu-VAL-HPh-FMK	Antibiotic	Infection
Calpain inhibitor V (Mu-Val-HPh-FMK) is a cell-permeable and irreversible inhibitor of calpain that has anti-chlamydial activity .

HY-W011254

Ac-VAD-CHO Ac-VAL-Ala-Asp-CHO	Caspase	Cancer
Ac-VAD-CHO (Ac-Val-Ala-Asp-CHO) is a pan-caspase inhibitor. Ac-VAD-CHO inhibits dissipation of MMP and cytochrome c release in hypoxia-exposed cells .

HY-P4900

Fluorescein-6-carbonyl-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone	Caspase	Others
Fluorescein-6-carbonyl-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone is a cell-permeable, non-toxic inhibitor that binds irreversibly to activated caspase-3 in apoptotic cells. The fluorescence intensity can be measured by flow cytometry, microwell plate reader, or fluorescence microscopy .

Cat. No.	Product Name	Target	Research Area

HY-P99612

Farletuzumab ecteribulin MORAb-202	Antibody-Drug Conjugates (ADCs)	Cancer
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

HY-P99803

Clervonafusp alfa VAL-1221	Glycosidase	Others
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .

Cat. No.	Product Name		Classification

HY-172287

DBCO-PEG2-Val-Cit-PAB-MMAE		DBCO
DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.

HY-W800814

Azido-PEG8-Amido-Val-Cit-PAB		Azide
Azido-PEG8-Amido-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome, the ADC payload will be released only in the cell. Azido will react with DBCO, BCN or other alkyne groups through click chemistry. PEG spacer increases aqueous solubility. Reagent grade, for research purpose.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: